Overview
- Dren Bio will receive $100 million upfront and is eligible for up to $1.7 billion in development, regulatory and commercial milestone payments.
- The collaboration focuses on next‑generation B‑cell depleting therapies for autoimmune diseases, a targeted approach used in conditions such as multiple sclerosis.
- The companies will jointly conduct discovery and preclinical work, with Sanofi assuming later‑stage development, manufacturing, regulatory and commercialization responsibilities.
- Dren Bio holds an option to co‑fund 40% of global development in exchange for U.S. co‑promotion and a 50/50 share of U.S. profits and losses, plus milestones and tiered royalties outside the U.S.
- The prior DR‑0201 program, now SAR448501, is in two phase 1 studies that have shown B‑cell depletion, though the announcement included no new clinical or regulatory readouts.